CANCER 2026 Paul Workman
Insitute of Cancer Research, , United Kingdom
Presentations this author is a contributor to:
Mechanistic deconvolution reveals DHODH as the key target of the KDM4 inhibitor QC6352 (#163)
5:40 PM
Jacinda JH Holtsmark
Welcome Reception & Poster Session 1
Clinical candidate drug NXP800 inhibits HSF1 pathway and activates the Integrated Stress Response (ISR) via GCN2 in ARID1A mutant ovarian cancer (#259)
5:35 PM
Maria E Taskinen
Poster Session 2